STRHÁRSKY, Tomáš, Dominika PINDJAKOVA, Jiří KOS, Lucia VRABLOVA, Pavel ŠMAK, Hana MICHNOVA, Tomáš GONĚC, Jan HOŠEK, Michal ORAVEC, Izabela JENDRZEJEWSKA, Alois ČÍŽEK a Josef JAMPILEK. Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, roč. 23, č. 23, s. 1-22. ISSN 1422-0067. Dostupné z: https://dx.doi.org/10.3390/ijms232315090.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections
Autoři STRHÁRSKY, Tomáš (703 Slovensko, domácí), Dominika PINDJAKOVA, Jiří KOS (203 Česká republika, garant, domácí), Lucia VRABLOVA, Pavel ŠMAK (203 Česká republika, domácí), Hana MICHNOVA, Tomáš GONĚC (203 Česká republika, domácí), Jan HOŠEK (203 Česká republika), Michal ORAVEC, Izabela JENDRZEJEWSKA, Alois ČÍŽEK (203 Česká republika) a Josef JAMPILEK.
Vydání International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2022, 1422-0067.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.600
Kód RIV RIV/00216224:14110/22:00127694
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/ijms232315090
UT WoS 000897240400001
Klíčová slova anglicky cinnamamides; Michael acceptors; antimicrobial activity; cytotoxicity; lipophilicity; structure-activity relationships; docking study
Štítky 14110512, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 30. 1. 2023 12:13.
Anotace
A series of thirty-two anilides of 3-(trifluoromethyl)cinnamic acid (series 1) and 4-(trifluoromethyl)cinnamic acid (series 2) was prepared by microwave-assisted synthesis. All the compounds were tested against reference strains Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 and resistant clinical isolates of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant E. faecalis (VRE). All the compounds were evaluated in vitro against Mycobacterium smegmatis ATCC 700084 and M. marinum CAMP 5644. (2E)-3-[3-(Trifluoromethyl)phenyl]-N-[4-(trifluoromethyl)phenyl]prop-2-enamide (1j), (2E)-N-(3,5-dichlorophenyl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide (1o) and (2E)-N-[3-(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)-phenyl]prop-2-enamide (2i), (2E)-N-[3,5-bis(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)phenyl]-prop-2-enamide (2p) showed antistaphylococcal (MICs/MBCs 0.15-5.57 mu M) as well as anti-enterococcal (MICs/MBCs 2.34-44.5 mu M) activity. The growth of M. marinum was strongly inhibited by compounds 1j and 2p in a MIC range from 0.29 to 2.34 mu M, while all the agents of series 1 showed activity against M. smegnatis (MICs ranged from 9.36 to 51.7 mu M). The performed docking study demonstrated the ability of the compounds to bind to the active site of the mycobacterial enzyme InhA. The compounds had a significant effect on the inhibition of bacterial respiration, as demonstrated by the MTT assay. The compounds showed not only bacteriostatic activity but also bactericidal activity. Preliminary in vitro cytotoxicity screening was assessed using the human monocytic leukemia cell line THP-1 and, except for compound 2p, all effective agents did show insignificant cytotoxic effect. Compound 2p is an interesting anti-invasive agent with dual (cytotoxic and antibacterial) activity, while compounds 1j and 1o are the most interesting purely antibacterial compounds within the prepared molecules.
Návaznosti
90123, velká výzkumná infrastrukturaNázev: CzeCOS III
VytisknoutZobrazeno: 7. 5. 2024 11:05